UAMY

United States Antimony Corporation

$2.23

-6.30%
Nov 20, 2026
Bobby Quantitative Model
United States Antimony Corporation is a vertically integrated mining, transportation, milling, smelting, and selling company operating two segments — antimony (including precious metals byproducts such as silver and gold) and zeolite — with the vast majority of revenue generated domestically in the United States. As one of the only domestic processors of antimony, a critical mineral used in flame retardants, batteries, and defense applications, UAMY occupies a strategically important but niche position in the Basic Materials sector, effectively functioning as a national-security supply-chain play rather than a conventional commodity miner. The investor narrative has become intensely binary: bulls point to the $245 million Defense Logistics Agency contract and first antimony shipments as validation of a structural re-rating story tied to U.S. critical-minerals policy, while bears focus on persistent operating losses, deeply negative free cash flow, and a drastic guidance cut that accompanied weak Q2 results. A $100 million buyback announcement briefly reignited management-confidence optimism, but with the stock down roughly 65% over the past year and trading near its 52-week low, the debate has shifted from growth optionality to execution credibility and financing risk.

People also watch

MP Materials

MP Materials

MP

Analysis
Materion

Materion

MTRN

Analysis
USA Rare Earth

USA Rare Earth

USAR

Analysis
Almirall

Almirall

ALM

Analysis
Critical Metals Corp. Ordinary Shares

Critical Metals Corp. Ordinary Shares

CRML

Analysis

BobbyInvestment Opinion: Should I buy UAMY Today?

Rating: Hold (speculative, small-position only). The core thesis is that UAMY's $245 million Defense Logistics Agency contract and its status as one of the only domestic processors of a designated critical mineral give it genuine strategic scarcity value, but at 15.81x price-to-sales against a Basic Materials norm of roughly 1.5-2.5x, a -$68.29 million TTM free cash flow burn, and a -94.0% Q3 2026 net margin, the equity currently prices in flawless execution that the financials do not yet support. The lone estimating analyst's $315.15 million average revenue forecast (versus a ~$40 million annualized run-rate) and the uniformly bullish rating tape (HC Wainwright Buy reiterated six times, B. Riley and D. Boral at Buy) anchor a constructive long-term view, but with no consensus price target and only one contributor, that consensus is a thin signal rather than broad conviction.

Supporting evidence cuts both ways. On the positive side, revenue rose sequentially from $6.78 million in Q1 2026 to $7.93 million in Q2 and $10.13 million in Q3 (+16.45% YoY), first antimony shipments under the DLA contract were delivered in early July 2026, the balance sheet carries effectively zero debt (debt-to-equity 0.0013) with a 5.38 current ratio and $30.87 million of cash, and the $245 million contract is roughly 6x the current run-rate. Against that, TTM gross margin is -4.35%, operating margin -22.61%, ROE -3.08%, and the Q3 gross margin of 42.4% follows a -70.3% print in Q1 and 7.4% in Q2 — cost volatility that makes earnings-based valuation impossible (trailing PE -142.6, EV/EBITDA -186.1). The 15.81x P/S is more than a 500% premium to sector norms, and the $30.87 million cash cushion was built on $48.9 million of equity issued in Q2 2026, with shares outstanding up ~21% from 123.6 million to 149.5 million in three quarters.

The biggest risks that could invalidate the thesis are (1) a delayed DLA ramp that leaves the $315 million consensus revenue unreachable and forces another equity raise at depressed prices, compounding dilution; (2) continued gross-margin volatility that keeps the company loss-making even as revenue scales; and (3) multiple compression — a re-rating from 15.8x toward even 5x sales would imply a share price near $0.75. This Hold would upgrade to Buy if the company posts two consecutive quarters of positive operating cash flow with gross margin sustained above 30%, or if the stock re-rates below roughly 8x forward sales on confirmed contract revenue; it would downgrade to Sell if Q4 2026 revenue fails to exceed the $10.13 million Q3 level, if another equity offering occurs before operating cash flow turns positive, or if the sole estimating analyst cuts the $315.15 million revenue forecast. Valuation verdict: the stock is cheaper than its own bubble-era multiples (P/S ranged from 8.2x in Q1 2024 to 182.2x in Q1 2026) but still expensive on any absolute measure for a loss-making, cash-burning operator — fairly valued only if the DLA ramp materializes on schedule, and materially overvalued if it does not.

Sign up to view all

UAMY 12-Month Price Forecast

The forward view is genuinely balanced: the $245 million DLA contract is roughly 6x the current run-rate and first shipments in July 2026 prove it is converting, but the -$68.29 million TTM cash burn and 15.81x P/S leave no margin for slippage, and the stock at $2.38 sits at its 52-week low with a -82.7% max drawdown behind it. The base case (50% probability, $2.60-4.20) assumes a gradual ramp well short of the $315.15 million consensus, with the bear case (30%, $1.20-2.38) driven by a financing event and the bull case (20%, $5.50-9.26) requiring visible cash-flow inflection. Analyst sentiment is uniformly positive but thin — one estimating analyst, no price target, and an 86% revenue-estimate spread — so it should be weighted lightly. I would upgrade to bullish on two consecutive quarters of positive operating cash flow with gross margin above 30%, and downgrade to bearish on any equity raise before cash flow turns or Q4 revenue below $10.13 million.

Historical Price
Current Price $2.23
Average Target $2.23
High Target $2.56
Low Target $1.90

Wall Street consensus

Coverage is extremely thin: only 1 analyst provides estimates, with an average estimated EPS of $0.465 (range $0.301–$0.679) and average estimated revenue of $315.15 million (range $229.7 million to $426.7 million) — a revenue forecast roughly 8x the current ~$40 million annualized run-rate, implying the Street expects a dramatic DLA-driven ramp. No consensus price target or Buy/Hold/Sell distribution is available in the provided data, so implied upside cannot be calculated; however, the institutional ratings history shows a uniformly bullish tape, with HC Wainwright reiterating Buy on 2026-08-12, 2026-05-18, 2026-03-23, 2026-02-03, 2025-11-13, and 2025-08-13, B. Riley initiating Buy on 2026-02-24, and D. Boral Capital at Buy on 2025-08-14 and 2025-05-12. The consensus therefore leans strongly bullish, but the absence of any Hold or Sell ratings from a tiny coverage group suggests limited independent scrutiny rather than genuine conviction.

The target range is not disclosed, but the dispersion in revenue estimates — $229.7 million low versus $426.7 million high, an 86% spread — signals very high uncertainty about the pace of contract conversion. The high end assumes full DLA contract ramp plus potential new critical-minerals awards and multiple expansion on a re-rating to domestic-supply-chain scarcity value; the low end prices in delayed shipments, margin compression from processing costs, and continued cash burn forcing further dilution. Notably, every rating in the dataset is a reiteration of Buy with no downgrades despite a 65% one-year decline and a guidance cut in August 2026, a pattern that raises questions about stale targets; with only one analyst contributing estimates and no target data, price discovery is likely inefficient, volatility should remain elevated, and investors should treat the bullish consensus with caution given the gap between $315 million consensus revenue and the current ~$40 million run-rate.

Drowning in data?

Find the real signal!

Bulls vs Bears: UAMY Investment Factors

The bear case currently carries stronger evidence: -$68.29 million TTM free cash flow, a -94.0% Q3 net margin, a 15.8x P/S multiple against a 1.5-2.5x sector norm, and a stock pinned at its $2.38 52-week low after a -82.7% max drawdown. The bull case rests almost entirely on one asset — the $245 million DLA contract — plus the genuine scarcity value of domestic antimony processing, and the first shipments in July 2026 are real validation that the contract is converting. The single most important tension is contract conversion speed versus cash burn: the lone analyst's $315.15 million revenue estimate is roughly 8x the current run-rate, and if shipments scale anywhere near that pace the 15.8x P/S compresses rapidly on forward sales, but if the ramp slips the company must raise more equity at depressed prices. With only one estimating analyst and no consensus price target, the bullish tape reflects thin coverage rather than broad conviction, so the debate is fundamentally about execution credibility and financing risk rather than demand for antimony.

Bullish

  • DLA contract provides $245M revenue anchor: The $245 million Defense Logistics Agency contract is roughly 6x the current ~$40 million annualized run-rate, and first antimony shipments were delivered in early July 2026, confirming the contract is converting rather than theoretical. The single analyst's average revenue estimate of $315.15 million implies the Street expects a multi-fold ramp tied to this award.
  • Scarcity value as domestic antimony processor: Antimony is a designated critical mineral, and UAMY is one of the only domestic processors, with 87% of Q3 2026 revenue ($8.83 million of $10.13 million) coming from antimony. This national-security positioning is the core reason a 15.8x P/S multiple has been sustained despite negative earnings, and it underpins the re-rating optionality if U.S. critical-minerals policy accelerates.
  • Pristine balance sheet with $30.87M cash: Debt-to-equity is effectively zero at 0.0013 and the current ratio is 5.38, with $30.87 million of cash at Q3 2026. That liquidity, though partly built from $48.9 million of equity issued in Q2 2026, gives the company runway to fund the DLA ramp without near-term solvency risk.
  • Sequential revenue improvement through 2026: Revenue rose from $6.78 million in Q1 2026 to $7.93 million in Q2 and $10.13 million in Q3, a 49% sequential increase from Q1 to Q3, and Q3 grew 16.45% year-over-year versus $8.70 million. The trajectory, while lumpy against Q4 2025's $13.03 million, shows the top line moving in the right direction as contract volumes begin.

Bearish

  • Cash burn of -$68.29M TTM free cash flow: Free cash flow TTM is -$68.29 million, with Q3 2026 alone at -$9.54 million and operating cash flow of -$4.00 million against $5.54 million of capex. The business consumes cash even before growth investment, and the PCF ratio of -64.0 confirms there is no internally generated funding for the DLA ramp.
  • Deeply negative and volatile profitability: Q3 2026 net income was -$9.53 million on a -94.0% net margin, with operating income of -$5.98 million (-59.0% operating margin) and EBITDA of -$8.57 million. Gross margin has swung from -70.3% in Q1 2026 to 7.4% in Q2 to 42.4% in Q3, showing cost volatility that makes any earnings-based valuation impossible (trailing PE -142.6, EV/EBITDA -186.1).
  • 15.8x P/S versus 1-3x sector norm: The price-to-sales ratio of 15.81x on a $620.6 million market cap compares with a Basic Materials norm of roughly 1.5-2.5x, a premium exceeding 500%. With a -11.05% net margin and -3.08% ROE, investors are paying a growth multiple for a loss-making operator, leaving little room for execution error.
  • Guidance cut and accelerating downtrend: A drastic guidance cut accompanied weak Q2 results in August 2026, and the stock has fallen 71.73% over six months and 56.65% over three months, with the 1-month decline of 23.72% steeper than the 1-year decline of 64.69%. At $2.38 the stock sits at its 52-week low with no established technical support beneath it and a max drawdown of -82.7%.

UAMY Technical Analysis

UAMY is locked in a severe, sustained downtrend, with the 1-year price change of -64.69% and a 6-month decline of -71.73% describing a near-continuous cascade from the mid-$9s in late May 2026 to the current $2.38. At $2.38, the stock sits at just 25.7% of its 52-week range (low $2.38, high $9.26), meaning it is pinned to the absolute bottom of its annual range — a positioning that historically signals either capitulation-grade value or a falling knife, and the absence of any meaningful bounce off prior support argues for the latter until proven otherwise. The max drawdown of -82.7% underscores how destructive this move has been for holders and how far overhead supply now sits.

Short-term momentum offers no relief: the 1-month change of -23.72% and 3-month change of -56.65% show the decline is accelerating rather than decelerating, with the most recent session alone shedding -5.56%. This is a textbook momentum divergence in the wrong direction — the 1-month trend is steeper than the 1-year trend, indicating selling pressure is intensifying, not mean-reverting, and relative strength versus the S&P 500 is deeply negative across every window (-16.80% over 1 month, -50.14% over 3 months, -72.72% over 1 year) against a SPY that is actually up 8.03% over the same year. Volume of roughly 5.25 million shares on a $620 million market cap suggests active distribution rather than quiet drift, and there is no RSI or volume-trend data provided to suggest an oversold bounce is imminent.

Key technical levels are stark: the 52-week low of $2.38 is the current price itself, so there is no established support beneath it — any further weakness enters price-discovery territory, while the 52-week high of $9.26 represents a 289% gap that would require a fundamental catalyst, not merely a technical rebound, to reclaim. Intermediate resistance likely forms around the $3.10–$3.47 zone where the stock repeatedly failed in October and early November 2026, and a breakout above that band would be the first credible sign of a trend change. Beta is not available in the provided data, but the -82.7% max drawdown and daily swings of 5–10% (e.g., $2.59 to $3.47 within three sessions in early November) imply volatility far in excess of the market, demanding materially smaller position sizing and wider stops than a typical Basic Materials name.

Beta

—

—

Max Drawdown

-83.4%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-62.1%

Cumulative gain past year

PeriodUAMY ReturnS&P 500
1m-32.2%-9.7%
3m-59.4%-9.9%
6m-73.5%-7.5%
1y-62.1%+4.7%
ytd-62.4%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

UAMY Fundamental Analysis

Revenue is growing but from a very small base and with erratic quality: Q3 2026 revenue of $10.13 million rose 16.45% year-over-year versus $8.70 million in Q3 2025, yet that figure declined sequentially from Q2 2026's $7.93 million... actually rose from $7.93 million, but fell sharply from Q4 2025's $13.03 million, illustrating a lumpy, contract-driven top line. Segment data shows antimony at $8.83 million (87% of revenue), zeolite at $1.04 million, and precious metals at just $0.27 million — the company is effectively a single-commodity story, so the DLA contract ramp is the entire growth thesis. The trajectory is not cleanly accelerating: Q1 2026 revenue of $6.78 million, Q2 $7.93 million, and Q3 $10.13 million show sequential improvement, but the 16.45% YoY growth rate is modest relative to the 15.8x sales multiple the market is being asked to pay.

Profitability is deeply negative and deteriorating at the operating line. Q3 2026 net income was -$9.53 million on a -94.0% net margin, with operating income of -$5.98 million (-59.0% operating margin) and EBITDA of -$8.57 million; the reported gross margin of 42.4% ($4.29 million gross profit) looks respectable but is flattered by comparison to Q1 2026's catastrophic -70.3% gross margin and Q2 2026's 7.4%, revealing wild quarter-to-quarter cost volatility. The Q3 loss was amplified by $4.43 million in other expenses and a -$3.35 million other-income line, while SG&A of $5.85 million consumed more than half of revenue. Trailing metrics confirm the pattern: net margin of -11.05%, operating margin of -22.61%, and gross margin of -4.35% on a TTM basis, with ROE of -3.08% — the company has not demonstrated a durable path to profitability despite the strategic narrative.

Balance-sheet strength is the one genuine bright spot, but cash burn is alarming. Debt-to-equity is effectively zero at 0.0013, the current ratio is a robust 5.38, and cash stood at $30.87 million at Q3 2026 — but that balance was propped up by $48.9 million of common stock issued in Q2 2026, i.e., dilution, not operations. Free cash flow TTM is -$68.29 million, Q3 2026 FCF alone was -$9.54 million, and operating cash flow was -$4.00 million against $5.54 million of capex, meaning the business consumes cash even before growth investment; the PCF ratio of -64.0 and EV/EBITDA of -186.1 are meaningless precisely because cash generation is negative. With inventory building (+$6.63 million in Q3) and a 486-day operating cycle, the company depends on external financing and its $100 million buyback authorization looks difficult to reconcile with negative operating cash flow.

Quarterly Revenue

$10133437.0B

2026-09

Revenue YoY Growth

+16.4%

YoY Comparison

Gross Margin

42.4%

Latest Quarter

Free Cash Flow

$-68285650.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Antimony
Precious Metals
Zeolite

Open an Account, get $2 TSLA now!

Valuation Analysis: Is UAMY Overvalued?

Because net income is negative (TTM EPS of -$0.007, Q3 2026 EPS of -$0.06) and EBITDA is also negative (-$8.57 million in Q3), neither the trailing PE of -142.6 nor the EV/EBITDA of -186.1 is meaningful; the appropriate primary metric is the price-to-sales ratio, which stands at 15.81x on a $620.6 million market cap. The forward PE of -1.19 and PEG of -1.19 are artifacts of negative forward earnings estimates and should be disregarded; the market is effectively pricing the company on revenue optionality from the DLA contract rather than on earnings, which is why the sales multiple is the only coherent anchor.

On a peer basis, a 15.8x P/S multiple is extraordinary for a Basic Materials/Industrial Materials company, where mature miners and processors typically trade at 1–3x sales; even high-growth specialty chemical names rarely exceed 5x. The premium is being justified — if at all — by the scarcity value of domestic antimony processing and the $245 million DLA contract, but the 4.40x price-to-book against a -3.08% ROE and -11.05% net margin means investors are paying a growth-stock multiple for a loss-making, cash-burning operator. The 15.8x P/S versus a sector norm of roughly 1.5–2.5x implies a premium of more than 500%, a spread that requires flawless contract execution to sustain.

Historical context is damning: UAMY's own P/S ratio has ranged from 8.2x (Q1 2024) to 182.2x (Q1 2026), and the current 15.8x sits in the lower quartile of that band — but the compression reflects a collapsing share price, not improving fundamentals, since revenue has grown only modestly while losses have widened. The P/B of 4.40x compares with 0.997x in Q1 2024 and 10.66x in Q3 2025, placing the current multiple in the middle of its historical range despite the stock being at 52-week lows, a paradox explained by heavy equity issuance inflating book value. In short, the stock is cheaper than its own recent bubble-era multiples but still expensive on any absolute measure for a company with negative margins and negative free cash flow.

PE

-142.6x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 22x~415x

vs. Industry Avg

25.2x

Industry PE ~25.2x*

EV/EBITDA

-186.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are acute and quantifiable. Free cash flow TTM of -$68.29 million against a $30.87 million cash balance implies roughly five months of runway at the current burn rate absent new financing, and the Q3 2026 cash position itself was built on $48.9 million of equity issued in Q2 2026 rather than operations. Revenue concentration is extreme: antimony was $8.83 million of Q3 2026's $10.13 million (87%), with zeolite at $1.04 million and precious metals at just $0.27 million, so the entire thesis hinges on a single commodity and a single customer relationship. Earnings quality is poor and volatile, with gross margin swinging from -70.3% in Q1 2026 to 42.4% in Q3, SG&A of $5.85 million consuming more than half of Q3 revenue, and a 486-day operating cycle with inventory building $6.63 million in the quarter. Market and competitive risks center on valuation compression. At 15.81x P/S versus a Basic Materials norm of roughly 1.5-2.5x, the stock embeds more than a 500% premium that requires flawless DLA execution; a re-rating toward even 5x sales would imply a share price near $0.75. Coverage is dangerously thin — one estimating analyst, no consensus price target, and an 86% spread between the $229.7 million low and $426.7 million high revenue estimates — meaning price discovery is inefficient and any single downgrade or estimate cut could move the stock violently. Relative strength versus the S&P 500 is -72.72% over one year against a SPY that is up 8.03%, and the August 2026 guidance cut alongside weak Q2 results shows how quickly sentiment reverses; the $100 million buyback authorization, announced while operating cash flow is negative, risks being read as capital misallocation rather than confidence. The worst-case scenario is a delayed DLA ramp combined with continued cash burn forcing another equity raise at depressed prices, which would compound dilution (shares already up ~21% from 123.6 million to 149.5 million in three quarters) while the sales multiple compresses. From the current $2.38, the stock is already at its 52-week low, so there is no technical support beneath it and further weakness enters price-discovery territory; a realistic adverse outcome is a further -30% to -50% toward the $1.20-$1.65 range, and the -82.7% max drawdown demonstrates that losses of that magnitude have already occurred once in this cycle. Investors should size positions assuming a total-loss tail scenario is plausible if financing markets close to the company.

FAQ

Ranked by severity: first, financing and dilution risk — free cash flow TTM of -$68.29 million against $30.87 million of cash implies roughly five months of runway, and the current cash was itself built on $48.9 million of equity issued in Q2 2026, with shares already up ~21% from 123.6 million to 149.5 million in three quarters. Second, execution and concentration risk — antimony was $8.83 million of Q3 2026's $10.13 million in revenue (87%), so the entire thesis hinges on one commodity and one customer, and the August 2026 guidance cut alongside weak Q2 results shows how fast the ramp can disappoint. Third, profitability volatility — gross margin swung from -70.3% in Q1 2026 to 7.4% in Q2 to 42.4% in Q3, with SG&A of $5.85 million consuming more than half of Q3 revenue and a 486-day operating cycle. Fourth, valuation and sentiment risk — 15.81x P/S versus a 1.5-2.5x norm, relative strength of -72.72% versus the S&P 500 over one year, and coverage by a single estimating analyst with no consensus price target, meaning one downgrade could move the stock violently.

The 12-month view is split three ways with the base case most likely at 50% probability and a $2.60-4.20 range, assuming the DLA contract ramps gradually rather than at the pace implied by the $315.15 million consensus, with free cash flow staying negative but the zero-debt balance sheet (debt-to-equity 0.0013) and $30.87 million of cash avoiding a solvency event. The bear case at 30% probability targets $1.20-2.38, driven by a delayed ramp, Q4 2026 revenue below the $10.13 million Q3 level, and another equity raise at depressed prices, consistent with the -82.7% max drawdown already experienced. The bull case at 20% probability targets $5.50-9.26 and requires quarterly revenue stepping toward $20-25 million, gross margin holding above 30%, and operating cash flow turning positive. The key assumption behind the base case is that the sole estimating analyst's $315.15 million revenue forecast proves roughly 8x too optimistic near-term but directionally correct over time — note the 86% spread between the $229.74 million low and $426.65 million high estimate, which itself signals how little visibility exists.

On any absolute measure the stock is overvalued; relative only to its own bubble-era history is it cheaper. With negative trailing EPS of -$0.007 and negative EBITDA of -$8.57 million in Q3 2026, the trailing PE of -142.6 and EV/EBITDA of -186.1 are meaningless, leaving price-to-sales as the only coherent anchor — and at 15.81x on a $620.6 million market cap, UAMY carries a premium exceeding 500% to the roughly 1.5-2.5x Basic Materials norm. The 4.40x price-to-book against a -3.08% ROE and -11.05% net margin confirms investors are paying a growth multiple for a loss-making operator. The one mitigating point is that UAMY's own P/S has ranged from 8.2x in Q1 2024 to 182.2x in Q1 2026, so 15.8x sits in the lower quartile of its historical band — but that compression came from a collapsing share price, not improving fundamentals. The market is effectively pricing flawless DLA conversion; a re-rating to even 5x sales would imply a share price near $0.75.

Only for investors who can tolerate a binary, potentially total-loss outcome and who size the position accordingly. The risk/reward is genuinely asymmetric in both directions: the $245 million DLA contract is roughly 6x the current ~$40 million annualized run-rate, and first shipments in July 2026 prove it is converting, which supports the bull case range of $5.50-9.26 (20% probability). Against that, free cash flow TTM is -$68.29 million against $30.87 million of cash, the stock trades at 15.81x sales versus a 1.5-2.5x sector norm, and it sits at its $2.38 52-week low after a -82.7% max drawdown, with the bear case at $1.20-2.38 (30% probability). There is no consensus price target to anchor implied upside, and coverage is a single estimating analyst, so the uniformly bullish rating tape is a thin signal. A good buy for a speculative, long-horizon investor who wants domestic antimony exposure and can wait for two quarters of positive operating cash flow; not a good buy for anyone needing earnings support, income, or near-term capital preservation.

UAMY is unsuitable for short-term trading for most investors and only conditionally suitable for long-term holding by risk-tolerant speculators. The volatility profile is extreme — a -82.7% max drawdown, a -23.72% one-month decline steeper than the -64.69% one-year decline, and single-session moves of -5.56% and +23% (the November 9 jump from $2.82 to $3.47) — which makes timing entries and exits exceptionally difficult without a fundamental catalyst calendar. There is no dividend (payout ratio 0) and no earnings visibility, since gross margin has ranged from -70.3% to 42.4% across three quarters, so there is no income or compounding rationale to justify a passive hold. The thesis is a multi-quarter, contract-conversion story: the DLA award runs well beyond 12 months, and the value only crystallizes if revenue scales toward the analyst's $315.15 million estimate and cash flow turns positive. A concrete minimum holding period of 18-24 months is appropriate, sized as a small speculative position, with the explicit understanding that a financing event or a Q4 revenue miss below $10.13 million would justify exiting rather than averaging down.